Skip to main content
Explore URMC
menu

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Research Question:
What is the safety, tolerability, and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in patients with untreated pancreatic cancer?

Basic Study Information

Purpose:
This is an open-label phase 1A/1B study to assess the safety, tolerability, and movement throughout the body (pharmacokinetics) of SBP-101 when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer (metastatic pancreatic ductal adenocarcinoma) and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.

Location: University of Rochester Medical Center
Study Reference #: IGIP19009

Lead Researcher (Principal Investigator)

Lead Researcher: Aram Hezel

Study Contact Information

Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: chris_lefeber@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search